Introduction: Percutaneous renal biopsy remains critical for the workup of renal
allograft dysfunction but is associated with the risk of bleeding. Prophylactic intravenous desmopressin has been proposed to reduce bleeding risk in native renal biopsies, but its efficacy in the renal transplant population is unclear and adverse events such as severe hyponatraemia have been reported. Materials and Methods: We conducted a single-centre retrospective cohort study involving adult (≥21 years old) renal transplant recipients with impaired renal function (serum creatinine ≥150 μmol/L) who underwent ultrasound-guided renal allograft biopsies from 2011‒2015 to investigate the effect of prebiopsy desmopressin on the risk of bleeding and adverse events. Results: Desmopressin was administered to 98 of 195 cases who had lower renal function, lower haemoglobin and more diuretic use.Postbiopsy bleeding was not significantly different between the 2 groups (adjusted odds ratio [OR] 0.79, 95% confidence interval [CI] 0.26‒2.43, P = 0.68) but desmopressin increased the risk of postbiopsy hyponatraemia (sodium [Na] <135 mmol/L) (adjusted OR 2.24, 95% CI 1.10‒4.59, P = 0.03). Seven cases of severe hyponatraemia (Na <125 mmol/L) developed in the desmopressin group, while none did in the non-desmopressin group. Amongst those who received desmopressin, risk of hyponatraemia was lower (OR 0.26, 95% CI 0.09‒0.72, P = 0.01) if fluid intake was <1 L on the day of biopsy. Conclusion: Prophylactic desmopressin for renal allograft biopsy may be associated with significant hyponatraemia but its effect on bleeding risk is unclear. Fluid restriction (where feasible)
should be recommended when desmopressin is used during renal allograft biopsy. A
randomised controlled trial is needed to clarify these outcomes.
Key words: Adverse effects, Deamino arginine vasopressin, Haematoma, Haemorrhage,
Hyponatraemia
read with interest the observational study by Peters et al. that found reduced minor and major complications after kidney biopsy among patients with serum creatinine ≥150 μmol/L. 1 The authors noted absence of negative sideeffects in their study but acknowledged that electrolyte derangements were not specifically examined. Based on a historical study of 269 transplant allograft biopsies where all received pre-biopsy desmopressin and none had symptomatic hyponatremia, 2 the authors opined that hyponatremia after a single dose of desmopressin was uncommon. However, the low incidence of desmopressin-induced hyponatremia in that study may be due to patients being administered only four 'units' of desmopressin before biopsy. 2 This dose appears much lower compared to the recommended dose of 0.3 μg/kg body weight administered subcutaneously or intravenously. 3,4 Nevertheless, we agree that there are little data on the prevalence of desmopressin-induced hyponatremia after kidney biopsies. Desmopressin is usually administered to individuals with impaired renal function to reduce uremic bleed, but these patients may be at increased risk of developing desmopressin-induced hyponatremia due to prolonged desmopressin half-life in renal dysfunction. In a recent retrospective cohort study of 423 native and allograft kidney biopsies with pre-biopsy serum creatinine ≥150 μmol/L and post-biopsy electrolytes checked based on clinical indications, severe hyponatremia with serum sodium <125 μmol/L occurred after 30 biopsies (7%) at median 2 (1, 4) days after kidney biopsy (abstract presented at the 55th ERA-EDTA Congress, Copenhagen 2018). Logistic regression taking into account age, biochemistry (pre-biopsy serum sodium, urea, estimated glomerular filtration rate, proteinuria) and medications (diuretic, desmopressin dose) found that higher desmopressin dose was independently associated with severe hyponatremia after kidney biopsy [adjusted OR 1.43 (95% CI 1.03, 1.98), P = 0.03].Since desmopressin-induced hyponatremia may be an under-recognized complication of kidney biopsy and associated with significant morbidity, 5 further studies will be required to identify at-risk individuals and determine if post-biopsy biochemistry surveillance is warranted among susceptible patients administered desmopressin to reduce bleeding complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.